Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express^™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology.

B-Body Express^™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express^™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future.

B-Body Express^™ - Validation Scale Service Features:

• Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales.
• Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation.
• Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility.
• Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon.
• Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms.

"Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express^™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability."

The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles—ideal for subcutaneous administration and standard manufacturing workflows.

Starting from validated partner sequences, B-Body Express^™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development.

About Invenra Inc.

Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express^™ service, to accelerate the journey of novel medicines to patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422436080/en/